Apolipoprotein A-IV: A protein intimately involved in metabolism

Journal of Lipid Research

Volumn 56, Issue 8, 2015, Pages 1403-1418

  Wang, Fei ^a   Kohan, Alison B ^b   Lo, Chun Min ^a   Liu, Min ^a   Howles, Philip ^a   Tso, Patrick ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Chylomicron; Diabetes; Glucose tolerance; Incretins; Intestinal lipid transport; Lymph fistula mouse model; Obesity

Indexed keywords

APOLIPOPROTEIN A4; CHOLECYSTOKININ; CHOLESTEROL; CHYLOMICRON; GLUCOSE; INCRETIN; INSULIN; LEPTIN; NEUROPEPTIDE; APOLIPOPROTEIN A; APOLIPOPROTEIN A-IV;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CIRCADIAN RHYTHM; DIABETES MELLITUS; DIET RESTRICTION; ENERGY METABOLISM; FOOD INTAKE; GENETIC REGULATION; GENETIC VARIABILITY; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; INTESTINE CELL; LIPID ABSORPTION; LIPOPROTEIN SYNTHESIS; LIVER METABOLISM; METABOLISM; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; ROUX Y ANASTOMOSIS; SATIETY; SMALL INTESTINE; STOMACH EMPTYING; STOMACH SECRETION; ANIMAL; GENE EXPRESSION REGULATION;

ANIMALS; APOLIPOPROTEINS A; BARIATRIC SURGERY; GENE EXPRESSION REGULATION; HUMANS; METABOLISM;

EID: 84930635918     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R052753     Document Type: Review

References (151)

1. Utermann, G., and U. Beisiegel. 1979. Apolipoprotein A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. Isolation and quantification. Eur. J. Biochem. 99: 333-343.
2. Green, P. H., R. M. Glickman, J. W. Riley, and E. Quinet. 1980. Human apolipoprotein A-IV. Intestinal origin and distribution in plasma. J. Clin. Invest. 65: 911-919.
3. Wu, A. L., and H. G. Windmueller. 1978. Identification of circulating apolipoproteins synthesized by rat small intestine in vivo. J. Biol. Chem. 253: 2525-2528.
4. Ghiselli, G., S. Krishnan, Y. Beigel, and A. M. Gotto, Jr. 1986. Plasma metabolism of apolipoprotein A-IV in humans. J. Lipid Res. 27: 813-827.
5. Ohta, T., N. H. Fidge, and P. J. Nestel. 1985. Studies on the in vivo and in vitro distribution of apolipoprotein A-IV in human plasma and lymph. J. Clin. Invest. 76: 1252-1260.
6. Borghini, I., F. Barja, D. Pometta, and R. W. James. 1995. Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim. Biophys. Acta. 1255: 192-200.
7. Ordovas, J. M., D. K. Cassidy, F. Civeira, C. L. Bisgaier, and E. J. Schaefer. 1989. Familial apolipoprotein A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J. Biol. Chem. 264: 16339-16342.
8. Cohen, R. D., L. W. Castellani, J. H. Qiao, B. J. Van Lenten, A. J. Lusis, and K. Reue. 1997. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J. Clin. Invest. 99: 1906-1916.
9. Duverger, N., G. Tremp, J. M. Caillaud, F. Emmanuel, G. Castro, J. C. Fruchart, A. Steinmetz, and P. Denèfle. 1996. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science. 273: 966-968.
10. Ostos, M. A., M. Conconi, L. Vergnes, N. Baroukh, J. Ribalta, J. Girona, J. M. Cailloud, A. Ochoa, and M. M. Zakin. 2001. Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21: 1023-1028.
11. Stein, O., Y. Stein, M. Lefevre, and P. S. Roheim. 1986. The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine. Biochim. Biophys. Acta. 878: 7-13.
12. von Eckardstein, A., Y. Huang, S. Wu, A. S. Sarmadi, S. Schwarz, A. Steinmetz, and G. Assman. 1995. Lipoproteins containing apolipoprotein a-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. Arterioscler. Thromb. Vasc. Biol. 15: 1755-1763.
13. Fournier, N., V. Atger, J. L. Paul, M. Sturm, N. Duverger, G. H. Rothblatt, and N. Moatti. 2000. Human apoA-IV overexpression in transgenic mice induces cholesterol efflux from J774 macrophages to whole serum. Arterioscler. Thromb. Vasc. Biol. 20: 1283-1292.
14. Gomaraschi, M., W. E. Putt, S. Pozzi, S. Iametti, A. Barbiroli, F. Bonomi, E. Favari, F. Bernini, G. Franceschini, P. J. Talmud, et al. 2010. Structure and function of the apoA-IV T347S and Q360H common variants. Biochem. Biophys. Res. Commun. 393: 126-130.
15. Qin, X., D. K. Swertfeger, S. Zheng, D. Y. Hui, and P. Tso. 1998. Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. Am. J. Physiol. 274: H1836-H1840.
16. Vowinkel, T., M. Mori, C. F. Krieglstein, J. Russell, F. Saijo, S. Bharwani, R. H. Turnage, W. S. Davidson, P. Tso, D. N. Granger, et al. 2004. Apolipoprotein A-IV inhibits experimental colitis. J. Clin. Invest. 114: 260-269.
17. Wang, F., A. B. Kohan, T. L. Kindel, K. L. Corbin, C. S. Nunemaker, S. Obici, S. C. Woods, W. S. Davidson, and P. Tso. 2012. Apolipoprotein A-IV improves glucose homeostasis by enhancing insulin secretion. Proc. Natl. Acad. Sci. USA. 109: 9641-9646.
18. Karathanasis, S. K. 1985. Apolipoprotein multigene family: Tandem organization of human apolipoprotein Ai, CIII, and AIV genes. Proc. Natl. Acad. Sci. USA. 82: 6374-6378.
19. Deng, X., J. Morris, J. Dressmen, M. R. Tubb, P. Tso, W. G. Jerome, W. S. Davidson, and T. B. Thompson. 2012. The structure of dimeric apolipoprotein A-IV and its mechanism of self-association. Structure. 20: 767-779.
20. Deng, X., J. Morris, C. Chaton, G. F. Schröder, W. S. Davidson, and T. B. Thompson. 2013. Small-angle X-ray scattering of apolipoprotein A-IV reveals the importance of its termini for structural stability. J. Biol. Chem. 288: 4854-4866.
21. Lohse, P., M. R. Kindt, D. J. Rader, and H. B. Brewer, Jr. 1991. Three genetic variants of human plasma apolipoprotein A-IV. apoA-IV-1(Thr347 - Ser), apoA-IV-0(Lys167 - Glu,Gln360 - His), and apoA-IV-3(Glu165 - Lys). J. Biol. Chem. 266: 13513-13518.
22. Menzel, H. J., H. Dieplinger, C. Sandholzer, I. Karádi, G. Utermann, and A. Császár. 1995. Apolipoprotein A-IV polymorphism in the Hungarian population: gene frequencies, effect on lipid levels, and sequence of two new variants. Hum. Mutat. 5: 58-65.
23. Bai, H., K. Saku, R. Liu, Y. Oribe, K. Yamamoto, and K. Arakawa. 1996. Polymorphism of the apolipoprotein A-IV gene and its significance in lipid metabolism and coronary heart disease in a Japanese population. Eur. J. Clin. Invest. 26: 1115-1124.
24. Talmud, P. J., E. Hawe, S. Martin, M. Olivier, G. J. Miller, E. M. Rubin, L. A. Pennacchio, and S. E. Humphries. 2002. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum. Mol. Genet. 11: 3039-3046.
25. Gomez, P., P. Perez-Martinez, C. Marin, A. Camargo, E. M. Yubero-Serrano, A. Garcia-Rios, F. Rodriguez, J. Delgado-Lista, F. Perez-Jimenez, and J. Lopez-Miranda. 2010. APOA1 and APOA4 gene polymorphisms influence the effects of dietary fat on LDL particle size and oxidation in healthy young adults. J. Nutr. 140: 773-778.
26. Hockey, K. J., R. A. Anderson, V. R. Cook, R. R. Hantgan, and R. B. Weinberg. 2001. Effect of the apolipoprotein A-IV Q360H polymorphism on postprandial plasma triglyceride clearance. J. Lipid Res. 42: 211-217.
27. Hubacek, J. A., R. Bohuslavova, Z. Skodova, J. Pitha, D. Bobkova, and R. Poledne. 2007. Polymorphisms in the APOA1/C3/A4/A5 gene cluster and cholesterol responsiveness to dietary change. Clin. Chem. Lab. Med. 45: 316-320.
28. Delgado-Lista, J., F. Perez-Jimenez, J. Ruano, P. Perez-Martinez, F. Fuentes, J. Criado-Garcia, L. D. Parnell, A. Garcia-Rios, J. M. Ordovas, and J. Lopez-Miranda. 2010. Effects of variations in the APOA1/C3/A4/A5 gene cluster on different parameters of postprandial lipid metabolism in healthy young men. J. Lipid Res. 51: 63-73.
29. Liu, Y., J. M. Ordovas, G. Gao, M. Province, R. J. Straka, M. Y. Tsai, C. Q. Lai, K. Zhang, I. Borecki, J. E. Hixson, et al. 2009. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study. Pharmacogenet. Genomics. 19: 161-169.
30. Qi, L., S. Liu, N. Rifai, D. Hunter, and F. B. Hu. 2007. Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes. Atherosclerosis. 192: 204-210.
31. Guclu-Geyik, F., A. Onat, N. Coban, E. Komurcu-Bayrak, V. Sansoy, G. Can, and N. Erginel-Unaltuna. 2012. Minor allele of the APOA4 gene T347S polymorphism predisposes to obesity in postmenopausal Turkish women. Mol. Biol. Rep. 39: 10907-10914.
32. Kretowski, A., J. E. Hokanson, K. McFann, G. L. Kinney, J. K. Snell-Bergeon, D. M. Maahs, R. P. Wadwa, R. H. Eckel, L. G. Ogden, S. K. Garg, et al. 2006. The apolipoprotein A-IV Gln360His polymorphism predicts progression of coronary artery calcification in patients with type 1 diabetes. Diabetologia. 49: 1946-1954.
33. Pennacchio, L. A., M. Olivier, J. A. Hubacek, J. C. Cohen, D. R. Cox, J. C. Fruchart, R. M. Krauss, and E. M. Rubin. 2001. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 294: 169-173.
34. Karathanasis, S. K., I. Yunis, and V. I. Zannis. 1986. Structure, evolution and tissue-specific synthesis of human apolipoprotein A-IV. Biochemistry. 25: 3962-3970.
35. Staels, B., A. van Tol, G. Verhoeven, and J. Auwerx. 1990. Apolipoprotein A-IV messenger ribonucleic acid abundance is regulated in a tissue-specific manner. Endocrinology. 126: 2153-2163.
36. Sanecka, A., M. Ansems, M. A. van Hout-Kuijer, M. W. Looman, A. C. Prosser, S. Welten, C. Gilissen, I. E. Sama, M. A. Huynen, J. A. Veltman, et al. 2012. Analysis of genes regulated by the transcription factor LUMAN identifies ApoA4 as a target gene in dendritic cells. Mol. Immunol. 50: 66-73.
37. Kalogeris, T. J., T. Tsuchiya, K. Fukagawa, R. Wolf, and P. Tso. 1996. Apolipoprotein A-IV synthesis in proximal jejunum is stimulated by ileal lipid infusion. Am. J. Physiol. 270: G277-G286.
38. Hanniman, E. A., G. Lambert, Y. Inoue, F. J. Gonzalez, and C. J. Sinal. 2006. Apolipoprotein A-IV is regulated by nutritional and metabolic stress: involvement of glucocorticoids, HNF-4 alpha, and PGC-1 alpha. J. Lipid Res. 47: 2503-2514.
39. Davidson, N. O., R. C. Carlos, M. J. Drewek, and T. G. Parmer. 1988. Apolipoprotein gene expression in the rat is regulated in a tissue-specific manner by thyroid hormone. J. Lipid Res. 29: 1511-1522.
40. Elshourbagy, N. A., M. S. Boguski, W. S. Liao, L. W. Jefferson, J. I. Gordon, and J. M. Taylor. 1985. Expression of rat apolipoprotein A-IV and A-I genes: mRNA induction during development and in response to glucocorticoids and insulin. Proc. Natl. Acad. Sci. USA. 82: 8242-8246.
41. Inui, Y., A. M. Hausman, N. Nanthakumar, S. J. Henning, and N. O. Davidson. 1992. Apolipoprotein B messenger RNA editing in rat liver: developmental and hormonal modulation is divergent from apolipoprotein A-IV gene expression despite increased hepatic lipogenesis. J. Lipid Res. 33: 1843-1856.
42. Williams, S. C., S. M. Bruckheimer, A. J. Lusis, R. C. LeBoeuf, and A. J. Kinniburgh. 1986. Mouse apolipoprotein A-IV gene: nucleotide sequence and induction by a high-lipid diet. Mol. Cell. Biol. 6: 3807-3814.
43. Srivastava, R. A., R. T. Kitchens, and G. Schonfeld. 1994. Regulation of the apolipoprotein AIV gene expression by estrogen differs in rat and mouse. Eur. J. Biochem. 222: 507-514.
44. Black, D. D., and H. Ellinas. 1992. Apolipoprotein synthesis in newborn piglet intestinal explants. Pediatr. Res. 32: 553-558.
45. Barbosa, S., G. Fasanella, S. Carriera, M. Llarena, R. Fox, C. Barreca, D. Andrew, and P. O'Hare. 2013. An orchestrated programme regulating secretory pathway genes and cargos by the transmembrane transcription factor CREB-H. Traffic. 14: 382-398.
46. Nagasawa, M., T. Hara, A. Kashino, Y. Akasaka, T. Ide, and K. Murakami. 2009. Identification of a functional peroxisome proliferator-activated receptor (PPAR) response element (PPRE) in the human apolipoprotein A-IV gene. Biochem. Pharmacol. 78: 523-530.
47. Sauvaget, D., V. Chauffeton, D. Citadelle, F. P. Chatelet, C. Cywiner-Golenzer, J. Chambaz, M. Pinçon-Raymond, P. Cardot, J. Le Beyec, and A. Ribeiro. 2002. Restriction of apolipoprotein A-IV gene expression to the intestine villus depends on a hormone-responsive element and parallels differential expression of the hepatic nuclear factor 4alpha and gamma isoforms. J. Biol. Chem. 277: 34540-34548.
48. Xu, X., J. Park, J. So, K. Y. Hur, and A. Lee. 2014. Transcriptional regulation of apolipoprotein A-IV by the transcription factor CREBH. J. Lipid Res. 55: 850-859.
49. Carrier, J. C., G. Deblois, C. Champigny, E. Levy, and V. Giguère. 2004. Estrogen-related receptor alpha (ERRalpha) is a transcriptional regulator of apolipoprotein A-IV and controls lipid handling in the intestine. J. Biol. Chem. 279: 52052-52058.
50. Kalogeris, T. J., K. Fukagawa, and P. Tso. 1994. Synthesis and lymphatic transport of intestinal apolipoprotein A-IV in response to graded doses of triglyceride. J. Lipid Res. 35: 1141-1151.
51. Kalogeris, T. J., F. Monroe, S. J. Demichele, and P. Tso. 1996. Intestinal synthesis and lymphatic secretion of apolipoprotein A-IV vary with chain length of intestinally infused fatty acids in rats. J. Nutr. 126: 2720-2729.
52. Imaizumi, K., M. Fainaru, and R. J. Havel. 1978. Composition of proteins of mesenteric lymph chylomicrons in the rat and alterations produced upon exposure of chylomicrons to blood serum and serum proteins. J. Lipid Res. 19: 712-722.
53. Hayashi, H., K. Fujimoto, J. A. Cardelli, D. F. Nutting, S. Bergstedt, and P. Tso. 1990. Fat feeding increases size, but not number, of chylomicrons produced by small intestine. Am. J. Physiol. 259: G709-G719.
54. Hayashi, H., D. F. Nutting, K. Fujimoto, J. A. Cardelli, D. Black, and P. Tso. 1990. Transport of lipid and apolipoproteins A-I and A-IV in intestinal lymph of the rat. J. Lipid Res. 31: 1613-1625.
55. Fujimoto, K., J. A. Cardelli, and P. Tso. 1992. Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation. Am. J. Physiol. 262: G1002-G1006.
56. Liu, M., T. Doi, L. Shen, S. C. Woods, R. J. Seeley, S. Zheng, A. Jackman, and P. Tso. 2001. Intestinal satiety protein apolipoprotein AIV is synthesized and regulated in rat hypothalamus. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280: R1382-R1387.
57. Liu, M., T. Doi, L. Shen, S. C. Woods, R. J. Seeley, S. Zheng, A. Jackman, and P. Tso. 2004. Obesity induced by a high-fat diet downregulates apolipoprotein A-IV gene expression in rat hypothalamus. Am. J. Physiol. Endocrinol. Metab. 287: E366-E370.
58. Yoshioka, M., C. Bolduc, V. Raymond, and J. St-Amand. 2008. High-fat meal-induced changes in the duodenum mucosa transcriptome. Obesity (Silver Spring). 16: 2302-2307.
59. Ferrer, F., E. Bigot-Corbel, P. N'Guyen, M. Krempf, and J. M. Bard. 2002. Quantitative measurement of lipoprotein particles containing both apolipoprotein AIV and apolipoprotein B in human plasma by a noncompetitive ELISA. Clin. Chem. 48: 884-890.
60. Ferrer, F., H. Nazih, Y. Zaïr, M. Krempf, and J. M. Bard. 2003. Postprandial changes in the distribution of apolipoprotein AIV between apolipoprotein B- and non apolipoprotein B-containing lipoproteins in obese women. Metabolism. 52: 1537-1541.
61. Vergès, B., B. Guerci, V. Durlach, C. Galland-Jos, J. L. Paul, L. Lagrost, and P. Gambert. 2001. Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: a study in normoponderal and obese subjects. J. Lipid Res. 42: 2021-2029.
62. Apfelbaum, T. F., N. O. Davidson, and R. M. Glickman. 1987. Apolipoprotein A-IV synthesis in rat intestine regulation by dietary triglyceride. Am. J. Physiol. 252: G662-G666.
63. Kalogeris, T. J., and R. G. Painter. 2001. Adaptation of intestinal production of apolipoprotein A-IV during chronic feeding of lipid. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280: R1155-R1161.
64. Kuller, L. H. 1997. Dietary fat and chronic diseases: epidemiologic overview. J. Am. Diet. Assoc. 97: S9-S15.
65. Liu, M., T. Doi, and P. Tso. 2003. Regulation of intestinal and hypothalamic apolipoprotein A-IV. Exp. Biol. Med. (Maywood). 228: 1181-1189.
66. Weinberg, R. B., C. Dantzker, and C. S. Patton. 1990. Sensitivity of serum apolipoprotein A-IV levels to changes in dietary fat content. Gastroenterology. 98: 17-24.
67. Fukagawa, K., H. M. Gou, R. Wolf, and P. Tso. 1994. Circadian rhythm of serum and lymph apolipoprotein AIV in ad libitum-fed and fasted rats. Am. J. Physiol. 267: R1385-R1390.
68. Liu, M., L. Shen, Y. Liu, D. Tajima, R. Sakai, S. C. Woods, and P. Tso. 2004. Diurnal rhythm of apolipoprotein A-IV in rat hypothalamus and its relation to food intake and corticosterone. Endocrinology. 145: 3232-3238.
69. Kohan, A. B., S. M. Yoder, and P. Tso. 2011. Using the lymphatics to study nutrient absorption and the secretion of gastrointestinal hormones. Physiol. Behav. 105: 82-88.
70. Nutting, D. F., N. S. Kumar, S. A. Siddiqi, and C. B. Mansbach 2nd. 2002. Nutrient absorption. Curr. Opin. Gastroenterol. 18: 168-175.
71. Tso, P., J. A. Balint, M. B. Bishop, and J. B. Rodgers. 1981. Acute inhibition of intestinal lipid transport by Pluronic L-81 in the rat. Am. J. Physiol. 241: G487-G497.
72. Tso, P., J. A. Balint, and J. B. Rodgers. 1980. Effect of hydrophobic surfactant (Pluronic L-81) on lymphatic lipid transport in the rat. Am. J. Physiol. 239: G348-G353.
73. Lu, S., Y. Yao, X. Cheng, S. Mitchell, S. Leng, S. Meng, J. W. Gallagher, G. S. Shelness, G. S. Morris, J. Mahan, et al. 2006. Overexpression of apolipoprotein A-IV enhances lipid secretion in IPEC-1 cells by increasing chylomicron size. J. Biol. Chem. 281: 3473-3483.
74. Weinberg, R. B., R. A. Anderson, V. R. Cook, F. Emmanuel, P. Denefle, M. Hermann, and A. Steinmetz. 2000. Structure and interfacial properties of chicken apolipoprotein A-IV. J. Lipid Res. 41: 1410-1418.
75. Gonzalez-Vallina, R., H. Wang, R. Zhan, H. M. Berschneider, R. M. Lee, N. O. Davidson, and D. D. Black. 1996. Lipoprotein and apolipoprotein secretion by a newborn piglet intestinal cell line (IPEC-1). Am. J. Physiol. 271: G249-G259.
76. Weinberg, R. B., J. W. Gallagher, M. A. Fabritius, and G. S. Shelness. 2012. ApoA-IV modulates the secretory trafficking of apoB and the size of triglyceride-rich lipoproteins. J. Lipid Res. 53: 736-743.
77. Yao, Y., S. Lu, Y. Huang, C. C. Beeman-Black, R. Lu, X. Pan, M. M. Hussain, and D. D. Black. 2011. Regulation of microsomal triglyceride transfer protein by apolipoprotein A-IV in newborn swine intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 300: G357-G363.
78. Chauhan, V., X. Wang, T. Ramsamy, R. W. Milne, and D. L. Sparks. 1998. Evidence for lipid-dependent structural changes in specific domains of apolipoprotein B100. Biochemistry. 37: 3735-3742.
79. Simon, T., V. R. Cook, A. Rao, and R. B. Weinberg. 2011. Impact of murine intestinal apolipoprotein A-IV expression on regional lipid absorption, gene expression, and growth. J. Lipid Res. 52: 1984-1994.
80. Kohan, A. B., F. Wang, X. Li, S. Bradshaw, Q. Yang, J. L. Caldwell, T. M. Bullock, and P. Tso. 2012. Apolipoprotein A-IV regulates chylomicron metabolism-mechanism and function. Am. J. Physiol. Gastrointest. Liver Physiol. 302: G628-G636.
81. Kohan, A. B., F. Wang, X. Li, A. E. Vandersall, S. Huesman, M. Xu, Q. Yang, D. Lou, and P. Tso. 2013. Is apolipoprotein A-IV rate limiting in the intestinal transport and absorption of triglyceride? Am. J. Physiol. Gastrointest. Liver Physiol. 304: G1128-G1135.
82. Fujimoto, K., K. Fukagawa, T. Sakata, and P. Tso. 1993. Suppression of food intake by apolipoprotein A-IV is mediated through the central nervous system in rats. J. Clin. Invest. 91: 1830-1833.
83. Fujimoto, K., H. Machidori, R. Iwakiri, K. Yamamoto, J. Fujisaki, T. Sakata, and P. Tso. 1993. Effect of intravenous administration of apolipoprotein A-IV on patterns of feeding, drinking and ambulatory activity of rats. Brain Res. 608: 233-237.
84. Liu, M., N. Maiorano, L. Shen, K. Pearson, D. Tajima, D. M. Zhang, S. C. Woods, R. J. Seeley, W. S. Davidson, and P. Tso. 2003. Expression of biologically active rat apolipoprotein AIV in Escherichia coli. Physiol. Behav. 78: 149-155.
85. Lo, C. M., D. M. Zhang, K. Pearson, L. Ma, W. Sun, R. R. Sakai, W. S. Davidson, M. Liu, H. E. Raybould, S. C. Woods, et al. 2007. Interaction of apolipoprotein AIV with cholecystokinin on the control of food intake. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293: R1490-R1494.
86. Lo, C. C., W. Langhans, M. Georgievsky, M. Arnold, J. L. Caldwell, S. Cheng, M. Liu, S. C. Woods, and P. Tso. 2012. Apolipoprotein AIV requires cholecystokinin and vagal nerves to suppress food intake. Endocrinology. 153: 5857-5865.
87. Hunt, J. N., and M. T. Knox. 1968. A relation between the chain length of fatty acids and the slowing of gastric emptying. J. Physiol. 194: 327-336.
88. Tso, P., and J. A. Balint. 1986. Formation and transport of chylomicrons by enterocytes to the lymphatics. Am. J. Physiol. 250: G715-G726.
89. Glatzle, J., T. J. Kalogeris, T. T. Zittel, S. Guerrini, P. Tso, and H. E. Raybould. 2002. Chylomicron components mediate intestinal lipid-induced inhibition of gastric motor function. Am. J. Physiol. Gastrointest. Liver Physiol. 282: G86-G91.
90. Glatzle, J., N. Darcel, A. J. Rechs, T. J. Kalogeris, P. Tso, and H. E. Raybould. 2004. Apolipoprotein A-IV stimulates duodenal vagal afferent activity to inhibit gastric motility via a CCK1 pathway. Am. J. Physiol. Regul. Integr. Comp. Physiol. 287: R354-R359.
91. Whited, K. L., D. Lu, P. Tso, K. C. Kent Lloyd, and H. E. Raybould. 2005. Apolipoprotein A-IV is involved in detection of lipid in the rat intestine. J. Physiol. 569: 949-958.
92. Okumura, T., K. Fukagawa, P. Tso, I. L. Taylor, and T. N. Pappas. 1994. Intracisternal injection of apolipoprotein A-IV inhibits gastric secretion in pylorus-ligated conscious rats. Gastroenterology. 107: 1861-1864.
93. Okumura, T., K. Fukagawa, P. Tso, I. L. Taylor, and T. N. Pappas. 1995. Mechanism of action of intracisternal apolipoprotein A-IV in inhibiting gastric acid secretion in rats. Gastroenterology. 109: 1583-1588.
94. Okumura, T., I. L. Taylor, K. Fukagawa, P. Tso, and T. N. Pappas. 1995. Apolipoprotein A-IV acts centrally in the brain to reduce the severity of gastric ulceration in the rat. Brain Res. 673: 153-156.
95. Okumura, T., K. Fukagawa, P. Tso, I. L. Taylor, and T. N. Pappas. 1996. Apolipoprotein A-IV acts in the brain to inhibit gastric emptying in the rat. Am. J. Physiol. 270: G49-G53.
96. Collins, S., C. M. Kuhn, A. E. Petro, A. G. Swick, B. A. Chrunyk, and R. S. Surwit. 1996. Role of leptin in fat regulation. Nature. 380: 677.
97. Frederich, R. C., A. Hamann, S. Anderson, B. Löllmann, B. B. Lowell, and J. S. Flier. 1995. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat. Med. 1: 1311-1314.
98. Considine, R. V., M. K. Sinha, M. L. Heiman, A. Kriauciunas, T. W. Stephens, M. R. Nyce, J. P. Ohannesian, C. C. Marco, L. J. McKee, and T. L. Bauer. 1996. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 334: 292-295.
99. Kelesidis, T., I. Kelesidis, S. Chou, and C. S. Mantzoros. 2010. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann. Intern. Med. 152: 93-100.
100. Havel, P. J. 2000. Role of adipose tissue in body-weight regulation: mechanisms regulating leptin production and energy balance. Proc. Nutr. Soc. 59: 359-371.
101. Schwartz, M. W., S. C. Woods, D. Porte, R. J. Seeley, and D. G. Baskin. 2000. Central nervous system control of food intake. Nature. 404: 661-671.
102. Shen, L., P. Tso, S. C. Woods, R. R. Sakai, W. S. Davidson, and M. Liu. 2007. Hypothalamic apolipoprotein A-IV is regulated by leptin. Endocrinology. 148: 2681-2689.
103. Doi, T., M. Liu, R. J. Seeley, S. C. Woods, and P. Tso. 2001. Effect of leptin on intestinal apolipoprotein AIV in response to lipid feeding. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281: R753-R759.
104. Banks, W. A., A. B. Coon, S. M. Robinson, A. Moinuddin, J. M. Shultz, R. Nakaoke, and J. E. Morley. 2004. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes. 53: 1253-1260.
105. Collins, S., and R. S. Surwit. 1996. Pharmacologic manipulation of ob expression in a dietary model of obesity. J. Biol. Chem. 271: 9437-9440.
106. Barrenetxe, J., A. C. Villaro, L. Guembe, I. Pascual, M. Muñoz-Navas, A. Barber, and M. P. Lostao. 2002. Distribution of the long leptin receptor isoform in brush border, basolateral membrane, and cytoplasm of enterocytes. Gut. 50: 797-802.
107. Guilmeau, S., M. Buyse, A. Tsocas, J. P. Laigneau, and A. Bado. 2003. Duodenal leptin stimulates cholecystokinin secretion: evidence of a positive leptin-cholecystokinin feedback loop. Diabetes. 52: 1664-1672.
108. Hansen, G. H., L-L. Niels-Christiansen, and E. M. Danielsen. 2008. Leptin and the obesity receptor (OB-R) in the small intestine and colon: a colocalization study. J. Histochem. Cytochem. 56: 677-685.
109. Plaisancie, P., R. Ducroc, M. El Homsi, A. Tsocas, S. Guilmeau, S. Zoghbi, O. Thibaudeau, and A. Bado. 2006. Luminal leptin activates mucin-secreting goblet cells in the large bowel. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G805-G812.
110. Morton, N. M., V. Emilsson, Y. L. Liu, and M. A. Cawthorne. 1998. Leptin action in intestinal cells. J. Biol. Chem. 273: 26194-26201.
111. Bado, A., S. Levasseur, S. Attoub, S. Kermorgant, J. P. Laigneau, M. N. Bortoluzzi, L. Moizo, T. Lehy, M. Guerre-Millo, Y. Le Marchand-Brustel, et al. 1998. The stomach is a source of leptin. Nature. 394: 790-793.
112. Sobhani, I., A. Bado, C. Vissuzaine, M. Buyse, S. Kermorgant, J. P. Laigneau, S. Attoub, T. Lehy, D. Henin, M. Mignon, et al. 2000. Leptin secretion and leptin receptor in the human stomach. Gut. 47: 178-183.
113. Cinti, S., R. D. Matteis, C. Picó, E. Ceresi, A. Obrador, C. Maffeis, J. Oliver, and A. Palou. 2000. Secretory granules of endocrine and chief cells of human stomach mucosa contain leptin. Int. J. Obes. Relat. Metab. Disord. 24: 789-793.
114. Oliver, P., C. Picó, R. De Matteis, S. Cinti, and A. Palou. 2002. Perinatal expression of leptin in rat stomach. Dev. Dyn. 223: 148-154.
115. Buyse, M., F. Berlioz, S. Guilmeau, A. Tsocas, T. Voisin, G. Peranzi, M. C. Laburthe, M. J. M. Lewin, C. Roze, and A. Bado. 2000. Intestinal epithelial cells express leptin receptors that modulate the oligopeptide transporter pept-1. Gastroenterology. 118: A604.
116. Cammisotto, P. G., and M. Bendayan. 2007. Leptin secretion by while adipose tissue and gastric mucosa. Histol. Histopathol. 22: 199-210.
117. Sobhani, I., M. Buyse, H. Goïot, N. Weber, J. P. Laigneau, D. Henin, J. C. Soul, and A. Bado. 2002. Vagal stimulation rapidly increases leptin secretion in human stomach. Gastroenterology. 122: 259-263.
118. Liddle, R. A., I. D. Goldfine, M. S. Rosen, R. A. Taplitz, and J. A. Williams. 1985. Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J. Clin. Invest. 75: 1144-1152.
119. Raybould, H. E. 1991. Capsaicin-sensitive vagal afferents and CCK in inhibition of gastric motor function induced by intestinal nutrients. Peptides. 12: 1279-1283.
120. Raybould, H. E., J. H. Meyer, Y. Tabrizi, R. A. Liddle, and P. Tso. 1998. Inhibition of gastric emptying in response to intestinal lipid is dependent on chylomicron formation. Am. J. Physiol. 274: R1834-R1838.
121. Debas, H. T., O. Farooq, and M. I. Grossman. 1975. Inhibition of gastric emptying is a physiological action of cholecystokinin. Gastroenterology. 68: 1211-1217.
122. Gibbs, J., R. C. Young, and G. P. Smith. 1973. Cholecystokinin decreases food intake in rats. J. Comp. Physiol. Psychol. 84: 488-495.
123. Zieve, L., B. Mulford, and A. McHale. 1966. Secretion of pancreatic enzymes. II. Comparative response following test meal or injection of secretin and pancreozymin. Am. J. Dig. Dis. 11: 685-694.
124. Mueller, K., and S. Hsiao. 1977. Specificity of cholecystokinin satiety effect: reduction of food but not water intake. Pharmacol. Biochem. Behav. 6: 643-646.
125. Moran, T. H., A. R. Baldessarini, C. F. Salorio, T. Lowery, and G. J. Schwartz. 1997. Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin. Am. J. Physiol. 272: R1245-R1251.
126. Deleted in proof.
127. Reidelberger, R. D., J. Hernandez, B. Fritzsch, and M. Hulce. 2004. Abdominal vagal mediation of the satiety effects of CCK in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286: R1005-R1012.
128. Sayegh, A. I., and R. C. Ritter. 2000. Vagus nerve participates in CCK-induced Fos expression in hindbrain but not myenteric plexus. Brain Res. 878: 155-162.
129. Green, G. M., S. Taguchi, J. Friestman, W. Y. Chey, and R. A. Liddle. 1989. Plasma secretin, CCK, and pancreatic secretion in response to dietary fat in the rat. Am. J. Physiol. 256: G1016-G1021.
130. Deleted in proof.
131. Melville, L. D., G. P. Smith, and J. Gibbs. 1993. Comparison of the satiating potencies of cholecystokinin-33 and cholecystokinin-8. Pharmacol. Biochem. Behav. 45: 85-87.
132. Wang, L., V. Martínez, M. D. Barrachina, and Y. Taché. 1998. Fos expression in the brain induced by peripheral injection of CCK or leptin plus CCK in fasted lean mice. Brain Res. 791: 157-166.
133. Yoshimichi, G., C. C. Lo, K. L. Tamashiro, L. Ma, D. M. Lee, D. P. Begg, M. Liu, R. R. Sakai, S. C. Woods, H. Yoshimatsu, et al. 2012. Effect of peripheral administration of cholecystokinin on food intake in apolipoprotein AIV knockout mice. Am. J. Physiol. Gastrointest. Liver Physiol. 302: G1336-G1342.
134. Shen, L., K. J. Pearson, Y. Xiong, C. M. Lo, P. Tso, S. C. Woods, W. S. Davidson, and M. Liu. 2008. Characterization of apolipoprotein A-IV in brain areas involved in energy homeostasis. Physiol. Behav. 95: 161-167.
135. Arnold, M., A. Mura, W. Langhans, and N. Geary. 2006. Gut vagal afferents are not necessary for the eating-stimulatory effect of intraperitoneally injected ghrelin in the rat. J. Neurosci. 26: 11052-11060.
136. Norgren, R., and G. P. Smith. 1994. A method for selective section of vagal afferent or efferent axons in the rat. Am. J. Physiol. 267: R1136-R1141.
137. Liu, M., L. Shen, T. Doi, S. C. Woods, R. J. Seeley, and P. Tso. 2003. Neuropeptide Y and lipid increase apolipoprotein AIV gene expression in rat hypothalamus. Brain Res. 971: 232-238.
138. Chambers, A. P., and S. C. Woods. 2012. The role of neuropeptide Y in energy homeostasis. Handb. Exp. Pharmacol. 209: 23-45.
139. Ebihara, K., Y. Ogawa, G. Katsuura, Y. Numata, H. Masuzaki, N. Satoh, M. Tamaki, T. Yoshioka, M. Hayase, N. Matsuoka, et al. 1999. Involvement of agouti-related protein, an endogenous antagonist of hypothalamic melanocortin receptor, in leptin action. Diabetes. 48: 2028-2033.
140. Hagan, M. M., S. C. Benoit, P. A. Rushing, L. M. Pritchard, S. C. Woods, and R. J. Seeley. 2001. Immediate and prolonged patterns of Agouti-related peptide-(83-132)-induced c-Fos activation in hypothalamic and extrahypothalamic sites. Endocrinology. 142: 1050-1056.
141. Gotoh, K., M. Liu, S. C. Benoit, D. J. Clegg, W. S. Davidson, D. D'Alessio, R. J. Seeley, P. Tso, and S. C. Woods. 2006. Apolipoprotein A-IV interacts synergistically with melanocortins to reduce food intake. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290: R202-R207.
142. Rodriguez, M. D., T. J. Kalogeris, X. L. Wang, R. Wolf, and P. Tso. 1997. Rapid synthesis and secretion of intestinal apolipoprotein A-IV after gastric fat loading in rats. Am. J. Physiol. 272: R1170-R1177.
143. Kim, W., and J. M. Egan. 2008. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev. 60: 470-512.
144. Li, X., M. Xu, F. Wang, A. B. Kohan, M. K. Haas, Q. Yang, D. Lou, S. Obici, W. S. Davidson, and P. Tso. 2014. Apolipoprotein A-IV reduces hepatic gluconeogenesis through the nuclear receptor NR1D1. J. Biol. Chem. 289: 2396-2404.
145. Weinberg, R. B., and C. S. Patton. 1990. Binding of human apolipoprotein A-IV to human hepatocellular plasma membranes. Biochim. Biophys. Acta. 1044: 255-261.
146. Tam, C. S., H. R. Berthoud, M. Bueter, M. V. Chakravarthy, A. Geliebter, A. Hajnal, J. Holst, L. Kaplan, W. Pories, H. Raybould, et al. 2011. Could the mechanisms of bariatric surgery hold the key for novel therapies? Report from a Pennington Scientific Symposium. Obes. Rev. 12: 984-994.
147. Beckman, L. M., T. R. Beckman, S. D. Sibley, W. Thomas, S. Ikramuddin, T. A. Kellogg, M. A. Ghatei, S. R. Bloom, C. W. le Roux, and C. P. Earthman. 2011. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery. JPEN J. Parenter. Enteral Nutr. 35: 169-180.
148. Culnan, D. M., R. N. Cooney, B. Stanley, and C. J. Lynch. 2009. Apolipoprotein A-IV, a putative satiety/antiatherogenic factor, rises after gastric bypass. Obesity (Silver Spring). 17: 46-52.
149. Adams, T. D., R. E. Gress, S. C. Smith, R. C. Halverson, S. C. Simper, W. D. Rosamond, M. J. Lamonte, A. M. Stroup, and S. C. Hunt. 2007. Long-term mortality after gastric bypass surgery. N. Engl. J. Med. 357: 753-761.
150. Raffaelli, M., C. Guidone, C. Callari, A. Iaconelli, R. Bellantone, and G. Mingrone. 2014. Effect of gastric bypass versus diet on cardiovascular risk factors. Ann. Surg. 259: 694-699.
151. Morínigo, R., V. Moizé, M. Musri, A. M. Lacy, S. Navarro, J. L. Marín, S. Delgado, R. Casamitjana, and J. Vidal. 2006. Glucagonlike peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J. Clin. Endocrinol. Metab. 91: 1735-1740.